Baluch Khoso

Director Baluch Khoso buys 2,269 shares of Processa Pharmaceuticals (PCSA) at $2.54; cluster of 8 other insiders bought within 14 days, stock down 78.3% from 52-week high of $11.97

Baluch Khoso, a director, purchased 2,269 shares at $2.54 on 2026-03-31, increasing his holdings from 56 shares to 2,325 shares—a +4051.8% increase in position size. This transaction is part of a coordinated cluster pattern, with 8 other insiders also buying within the past 14 days. The insider's cross-ticker track record shows strong historical performance: 3 prior buys with an average 30-day return of +315.7% and an average 90-day return of +85.3%, with a 100.00% 90-day win rate. However, Processa trades at $2.60, down 78.3% from its 52-week high of $11.97, and the company reported zero revenue in its latest quarter with a net loss of $-3,436,573.00. The combination of broad insider accumulation, director participation, and aggressive repricing creates a notable signal, but the company's unprofitable fundamentals and depressed valuation require investor scrutiny of whether the cluster buying reflects anticipated operational improvement or represents bottom-fishing in a distressed equity.

Director Baluch Khoso buys 11,766 shares of LGVN; prior buys at this ticker showed 458.8% and 473.2% 30-day returns, but stock now -67.7% from 52-week high.

Baluch Khoso, a director, purchased 11,766 shares, increasing his holdings by 28.9% to 52,516 shares. His prior two purchases at LGVN (on 2023-12-29 and 2023-12-28) both demonstrated strong 30-day gains of 458.8% and 473.2% respectively, and each delivered positive 90-day returns (127.0% and 122.8%), establishing a pattern of well-timed entry points at this ticker. However, the current investment environment presents a starkly different backdrop: LGVN stock stands 67.7% below its 52-week high and has declined 39.4% over the past 30 days, while the company remains unprofitable with a net loss of $5.0M against quarterly revenue of only $316.0K. The substantial discount from prior highs and the director's history of successful timing at this ticker merit investor attention, but the company's deteriorating financial trajectory and depressed valuation warrant scrutiny of the underlying business health before any extrapolation from prior buy-side outcomes.